retatrutide triple agonist glp-1 gip glucagon phase 3 2025 Lilly's achieves 16.8% weight loss in trial First Retatrutide phase 3 data,

Call your doctor right away if you have serious side effects

Soliqua 100/33 (active ingredients: insulin glargine and lixisenatide) subcutaneous injection Initial FDA Approval: 2016 Side Effect Update Date: May 28, 2025 Medication Description: Treats type 2 diabetes Updated Side Effects/Safety Information: A new warning section on Severe Gastrointestinal Adverse Reactions. An additional new warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting

These differences highlight the risks of overgeneralization and the considerable gaps in epidemiological data from low and middle income countries

In emergency situations, patients should always be assumed to be non-fasting

They aid in the treatment of type 2 diabetes and encourage weight reduction